Innovent Biologics Closes Strategic Partnership with Takeda
Innovent Biologics has closed a global strategic partnership with Takeda, fulfilling their License, Option, and Collaboration Agreement, and Share Issuance Agreement. This led to the issuance of 6,913,834 shares, raising approximately HK$778 million. The partnership enhances Innovent's strategic positioning and financial resources for developing biologic medicines. The latest analyst rating for Innovent's stock (HK:1801) is a Hold with a HK$101.00 price target. Innovent Biologics focuses on innovative therapies in the pharmaceutical industry.
Tip Ranks·
